Geschlechtersensible medizinische Ansätze in der Kardiologie

Die geschlechtersensible personalisierte Medizin berücksichtigt sowohl biologische als auch soziokulturelle Geschlechterunterschiede bei der Erhaltung von Gesundheit und bei der Entstehung von kardiovaskulären Erkrankungen. Dieser Ansatz ermöglicht es, geschlechterspezifische Gesundheitsfaktoren zu identifizieren und individuellere Präventionsmaßnahmen anzubieten.

Abstract

Gender-sensitive medicine takes into account differences of men and women in various diseases with regard to the biological („sex“) as well as the sociocultural („gender“) dimension. This article highlights gender differences in cardiovascular disease and the different prevention strategies based on these differences.

Schlüsselwörter

Geschlechterunterschiede - Kardiologie - Gendergeschlecht - Herzinsuffizienz - Medikamente

Keywords

gender differences - cardiology - gender sex - heart failure - medications

• Literatur

• 1 Tsugawa Y, Jena AB, Figueroa JF. et al. Comparison of Hospital Mortality and Readmission Rates for Medicare Patients Treated by Male vs Female Physicians. JAMA Intern Med 2017; 177: 206-213
• 2 Litviňuková M, Talavera-López C. et al. Cells of the adult human heart. Nature 2020; 588: 466-472
• 3 Charbit B, Christin-Maître S, Démolis JL. et al. Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol 2009; 103: 887-890
• 4 De Leo V, la Marca A, Agricola E. et al. Resting ECG is modified after oophorectomy and regresses with estrogen replacement therapy in premenopausal women. Maturitas 2000; 36: 43-47
• 5 Wang Y, Stuart JJ, Rich-Edwards JW. et al. Menstrual Cycle Regularity and Length Across the Reproductive Lifespan and Risk of Cardiovascular Disease. JAMA Netw Open 2022; 5: e2238513
• 6 Liang C, Chung H, Dobson A J. et al. Infertility, recurrent pregnancy loss, and risk of stroke: pooled analysis of individual patient data of 618 851 women. BMJ 2022; 377: e070603
• 7 Seeland U. Kommentar zu „Schlaganfall: Fehl- und Totgeburten als Risikofaktoren?. “ Dtsch Med Wochenschr 2022; 147: 1237-1237
• 8 Lo CCW, Lo ACQ, Leow SH. et al. Future Cardiovascular Disease Risk for Women With Gestational Hypertension: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2020; 9: e013991
• 9 Iorga A, Cunningham CM, Moazeni S. et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ 2017; 24: 33
• 10 Seeland U, Demuth I, Regitz-Zagrosek V. et al. Sex differences in arterial wave reflection and the role of exogenous and endogenous sex hormones: results of the Berlin Aging Study II. J Hypertens 2020; 38: 1040-1046
• 11 Pelletier R, Khan NA, Cox J. et al. Sex Versus Gender-Related Characteristics: Which Predicts Outcome After Acute Coronary Syndrome in the Young?. JACC 2016; 67: 127-135
• 12 Canto JG, Shlipak MG, Rogers WJ. et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000; 283: 3223-3229
• 13 Canto JG, Rogers WJ, Goldberg RJ. et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA 2012; 307: 813-822
• 14 Johnston N, Schenck-Gustafsson K, Lagerqvist B. Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain?. Eur Heart J 2011; 32: 1331-1336
• 15 Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol 2009; 54: 1561-1575
• 16 Murthy VL, Naya M, Taqueti VR. et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 2014; 129: 2518-2527
• 17 Ong P, Athanasiadis A, Borgulya G. et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation 2014; 129: 1723-1730
• 18 Nauman AT, Teren A, Zeynalova S. et al. Nonobstructive Coronary Artery Disease at Angiography and Gender-Specific Indicators for Cardiovascular Events: 5-Year Follow-Up of the LIFE Heart Study. J Womens Health 2020; 29: 338-344
• 19 Cleland JG, Swedberg K, Follath F. et al. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-463
• 20 Owan TE, Hodge DO, Herges RM. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259
• 21 Packer M, Lam CSP, Lund LH. et al. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail 2020; 22: 1551-1567
• 22 Seeland U, Brecht A, Nauman AT. et al. Prevalence of arterial stiffness and the risk of myocardial diastolic dysfunction in women. Biosci Rep 2016; 36: e00400
• 23 Templin C, Ghadri JR, Diekmann J. et al. Clinical features and outcomes of Takotsubo (stress) Cardiomyopathy. N Engl J Med 2015; 373: 929-938
• 24 Anker SD, Butler J, Fillipatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385: 1451-1461
• 25 Solomon SD, McMurray JJV, Claggett B. et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387: 1089-1098
• 26 Wu Z, Zhou P, He N. et al. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system. Front Cardiovasc Med 2022; 9: 966331
• 27 Sperling H. Erektions- und Ejakulationsstörungen. In: Rausch S, Stenzel A. Männermedizin. Kap. 3.6. München: Elsevier Urban & Fischer; 2022